Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study

Overview of attention for article published in Frontiers in Pharmacology, February 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 21 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 6,206 followers.

RT @GrymonprezMaxim: Nationwide study with 254,478 AF patients: 1. NOACs vs VKAs: superior effectiveness, non-inferior to superior safety…

02 Feb 2023

Reply Repost Favourite

RT @FrontPharmacol: New Research: Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patie…

02 Feb 2023

Reply Repost Favourite

New Research: Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study https://t.co/4xNwdLJ6Uf #pharmacology

02 Feb 2023

Reply Repost Favourite

Nationwide study with 254,478 AF patients: 1. NOACs vs VKAs: superior effectiveness, non-inferior to superior safety 2. NOACs vs NOACs: -> Comparable effectiveness -> Differential safety: lower major bleeding risk with api/dabi vs riva & api vs

02 Feb 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.